The plasma levels of soluble P-selectin in subjects with prediabetes

International Journal of Clinical Practice

Volumn 60, Issue 9, 2006, Pages 1048-1052

  Dogru, Teoman ^a   Tasci, I ^a   Sonmez, A ^a   Genc, H ^a   Gok, M ^a   Yilmaz, M I ^a   Ural, A U ^a   Olgun, A ^a   Kilic, S ^a   Bozoglu, E ^a   Erdem, G ^a   Erbil, K ^a  

^a GULHANE SCHOOL OF MEDICINE   (Turkey)

Author keywords

Impaired fasting glucose; Impaired glucose tolerance; Prediabetes; Soluble P selectin

Indexed keywords

C REACTIVE PROTEIN; PADGEM PROTEIN;

ADULT; ARTICLE; ATHEROGENESIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CONTROLLED STUDY; DATA ANALYSIS; FEMALE; HUMAN; IMPAIRED GLUCOSE TOLERANCE; MALE; MORTALITY; PRIORITY JOURNAL; RISK FACTOR; STATISTICAL ANALYSIS; THROMBOCYTE ACTIVATION; THROMBOSIS;

C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; FEMALE; GLUCOSE INTOLERANCE; HUMANS; MALE; MIDDLE AGED; P-SELECTIN; PREDIABETIC STATE; RISK FACTORS;

EID: 33747163929     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2006.00969.x     Document Type: Article

References (41)

1. Luscher TF, Creager MA, Beckman JA et al. Diabetes and vascular disease: pathophysiology, clinical consequences and medical therapy. Circulation 2003; 108: 1655-61.
2. Haffner SM, Lehto S, Ronnemaa T et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229-34.
3. Beckman JA, Creager M, Libby P. Diabetes and atherosclerosis. Epidemiology, pathophysiology and management. JAMA 2002; 287: 2570-81.
4. Kahn SE. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes. Diabetologia 2003; 46: 3-19.
5. Haffner SM. Impaired glucose tolerance, insulin resistance and cardiovascular disease. Diabet Med 1997; 14: 12-8.
6. Haffner SM, Mykkänen L, Festa A et al. Insulin-resistant prediabetic subjects have more atherogenic risk factors than insulin-sensitive prediabetic subjects. Implications for preventing coronary heart disease during the prediabetic state. Circulation 2000; 101: 975-80.
7. Hu FB, Stampfer MJ, Haffner SM et al. Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes. Diabetes Care 2002; 25: 1129-34.
8. McEver RP. Properties of GMP-140, an inducible granule membrane protein of platelets and endothelium. Blood Cells 1990; 16: 73-80.
9. Thomas FT, Douglas AS, Anjun C et al. The selectins: Vascular adhesion molecules. FASEB J 1995; 9: 866-73.
10. Berman CL, Yeo EL, Wencel-Drake JD et al. A platelet alpha granule membrane protein that is associated with the plasma membrane after activation. J Clin Invest 1986; 78: 130-7.
11. McEver R. GMP-140: A receptor for neutrophils and monocytes on activated platelets and endothelium. J Cell Biochem 1991; 45: 156-61.
12. Parmentier S, McGregor L, Catimel B et al. Inhibition of platelet functions by a monoclonal antibody (LYP20) directed against a granule membrane glycoprotein (GMP-140/PAD- GEM). Blood 1991; 77: 1734-9.
13. Blann AD, Lip GYH. Hypothesis: Is soluble P-selectin a new marker of platelet activation?. Atherosclerosis 1997; 128: 135-8.
14. Blann AD, Lip GYH, Beevers DG et al. Soluble P-selectin in atherosclerosis: A comparison with endothelial cell and platelet markers. Thromb Haemost 1997; 77: 1077-80.
15. Blann AD, Faragher EB, McCollum CN. Increased soluble P-selectin following myocardial infarction. a new marker for the progression of atherosclerosis. Blood Coagul Fibrinol 1997; 8: 383-90.
16. Blann AD, Seigneur M, Boisseau MR et al. Soluble P selectin in peripheral vascular disease: Relationship to the location and extent of atherosclerotic disease and its risk factors. Blood Coagul Fibrinol 1996; 7: 789-93.
17. Ikeda H, Takajo Y, Ichiki K et al. Increased soluble form of P- selectin in patients with unstable angina. Circulation 1995; 92: 1693-6.
18. Jilma B, Fasching P, Ruthner C et al. Elevated circulating P-selectin in insulin dependent diabetes mellitus. Thromb Haemost 1996; 76: 328-32.
19. Kopp H-P, Hopmeier P, Schernthaner G. Concentrations of circulating P-selectin are increased in patients with newly diagnosed insülin-dependent diabetes mellitus. Exp Clin Endocrinol Diabetes 1998; 106: 41-4.
20. Ridker PM, Buring JE, Rifai N. Soluble P-selectin and the risk of future cardiovascular events. Circulation 2001; 103: 491-5.
21. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2004; 27: 5-10.
22. Friedwald WT, Levy R, Fredrickson DS. Estimation of serum low-density lipoprotein without the use of a preparative ultracentrifuge. Clin Chem 1978; 18: 499-502.
23. Wasunna A, Whitelaw A, Gallmore JR et al. C-reactive protein and bacterial infection in preterm infants. Eur J Pediatr 1990; 149: 424-7.
24. Matthews DR, Hosker JP, Rudenski AS et al. Homeostasis model assessment: insulin resistance and B-cell function from plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-9.
25. Frenette PS, Johnson RC, Hynes RO. Platelets roll on stimulated endothelium in vivo: An interaction mediated by endothelial P-selectin. Proc Natl Acad Sci USA 1995; 92: 7450-4.
26. Johnson RC, Chapman SM, Dong ZM. Absence of P-selectin delays fatty streak formation in mice. J Clin Invest 1997; 99: 1037-43.
27. Dong ZM, Brown AA, Wagner DD. Prominent role of P-selectin in the development of advance atherosclerosis in apoE-deficient mice. Circulation 2000; 101: 2290-5.
28. Nageh MF, Sandberg ET, Marotti KR. Deficiency of inflammatory cell adhesion molecules protects against atherosclerosis in mice. Arterioscler Thromb Vasc Biol 1997; 17: 1511-20.
29. Ramos CL, Hup Y, Jung U. Direct demonstration of P-selectin and VCAM-1 dependent mononuclear cell rolling in early atherosclerotic lesions of apolipoprotein E- deficient mice. Circ Res 1999; 84: 1237-44.
30. Lip GY, Blann AD, Zarifis J. Soluble adhesion molecule P-selectin and endothelial dysfunction in essential hypertension; implications for atherogenesis?. J Hypertens 1995; 13: 1674-8.
31. Davi G, Romano M, Mezzetti A. Increased levels of soluble P- selectin in hypercholesterolemic patients. Circulation 1998; 97: 953-7.
32. Blann AD, Dobrotova M, Kubizs P. Von Willebrand factor, soluble P-selectin, tissue plasminogen activator inhibitor in atherosclerosis. Thromb Haemost 1995; 74: 626-30.
33. Sakurai S, Inoue A, Koh CS. Soluble form of selectins in blood of patients with acute myocardial infarction and coronary intervention. Vasc Med 1997; 2: 163-8.
34. Shimomura H, Ogawa H, Arai H. Serial changes in plasma levels of soluble P- selectin in patients with acute myocardial infarction. Am J Cardiol 1998; 81: 397-400.
35. Gokulakrishnan K, Deepa R, Mohan V et al. Soluble P-selectin and CD40L levels in subjects with prediabetes, diabetes mellitus, and metabolic syndrome-the Chennai Urban Rural Epidemiology Study. Metabolism 2006; 55: 237-42.
36. Levitan EB, Song Y, Ford ES et al. Is nondiabetic hyperglycemia a risk factor for cardiovascular disease? A meta-analysis of prospective studies. Arch Intern Med 2004; 164: 2147-55.
37. Haffner SM. Pre-diabetes, insulin resistance, inflammation and CVD risk. Diabetes Res Clin Pract 2003; 61: 9-28.
38. Hanley AJG, Williams K, Stern MP et al. Homeostasis model assessment of insulin resistance in relation to the incidence of cardiovascular disease. Diabetes Care 2002; 25: 1177-84.
39. Festa A, Hanley AJ, Tracy RP et al. Inflammation in the prediabetic state is related to increased insulin resistance rather than decreased insulin secretion. Circulation 2003; 108: 1822-30.
40. Han TS, Sattar N, Williams K et al. Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City Diabetes Study. Diabetes Care 2003; 26: 1656-7.
41. Temelkova-Kurktschiev T, Siegert G, Bergmann S et al. Subclinical inflammation is strongly related to insulin resistance but not to impaired insulin secretion in a high risk population for diabetes. Curr Opin Lipidol 2003; 14: 329-32.